Team Strengthened ahead of Commercialisation Phase

Respiratory pharmaceutical company Senzer has expanded its Board and reshaped its executive team under changes aimed at bolstering its commercialisation strategy for COVID-19 and cannabinoid treatments.

Senzer’s new chairman, Barbara Staehelin, is a serial entrepreneur who founded four life science companies and has had an executive role with Roche Diagnostics. She will be joined on the board by non-executive directors, Tim Corn, CMO at Izana Bioscience and Andy Weymann who served as CMO to Smith and Nephew.

Former CEO Alex Hearn, founder and inventor of the inhalation platform at the heart of the Company, will remain actively involved in the business as Deputy Chairman and will continue to assist the Company on scientific and technical strategy. Adam Kelliher, who has been involved with the company for more than two years as Chairman and Executive Chairman, has strong commercialisation expertise and becomes CEO.

Qualified doctor Matt McKevitt has been promoted to COO and Dr Andrew Saich, previously International Medical Director at GW Pharmaceuticals, will become CMO. Wendy Lloyd-Goodwin, previously head of legal and compliance at Bristol Myers Squibb (UK.EIR) will be Senzer’s General Counsel. They will join the executive team with Chief Financial Officer (CFO) Nick Robbins-Cherry, who has more than 25 years’ experience in US and UK public markets.

 “We now have in place a highly experienced executive team and a very focused Board. These appointments are crucial as our unique respiratory offerings will soon be ready for patients and users,  We all owe so much to Alex Hearn, under whose leadership Senzer has developed a remarkable product pipeline that enables us to now take the company into a commercial execution phase,” said Adam Kelliher.